Literature DB >> 8630237

Role of dihydrotestosterone in androgen action.

J D Wilson1.   

Abstract

Androgen action differs from that of most hormones in the testosterone, the major androgen secreted from the testes and the most abundant androgen in the circulation of men, is not the principal androgen within target cells. Indeed, abundant evidence indicates that most androgen actions are mediated by the 5alpha-reduced metabolite dihydrotestosterone that is formed in target tissues. The conversion of testosterone to dihydrotestosterone is mediated by two isoenzymes; mutations in the steroid 5alpha-reductase 2 gene cause a rare autosomal-recessive form of male pseudohermaphroditism, and inhibition of this enzyme causes regression of the prostate gland. Dihydrotestosterone binds more tightly to the androgen receptor that does testosterone, but it is not clear whether this property is the sole explanation for its essential role in androgen action. Nor is it clear whether some androgenic effects may be mediated by circulating dihydrotestosterone acting as a hormone.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8630237

Source DB:  PubMed          Journal:  Prostate Suppl        ISSN: 1050-5881


  10 in total

1.  Androgen regulation of prostate morphoregulatory gene expression: Fgf10-dependent and -independent pathways.

Authors:  Yongbing Pu; Liwei Huang; Lynn Birch; Gail S Prins
Journal:  Endocrinology       Date:  2007-01-11       Impact factor: 4.736

2.  Low complication rates of testosterone and estradiol implants for androgen and estrogen replacement therapy in over 1 million procedures.

Authors:  Gary S Donovitz
Journal:  Ther Adv Endocrinol Metab       Date:  2021-05-27       Impact factor: 3.565

3.  Androgen regulation of 5α-reductase isoenzymes in prostate cancer: implications for prostate cancer prevention.

Authors:  Jin Li; Zhiyong Ding; Zhengxin Wang; Jing-Fang Lu; Sankar N Maity; Nora M Navone; Christopher J Logothetis; Gordon B Mills; Jeri Kim
Journal:  PLoS One       Date:  2011-12-14       Impact factor: 3.240

4.  The impact of point mutations in the human androgen receptor: classification of mutations on the basis of transcriptional activity.

Authors:  Colin W Hay; Iain J McEwan
Journal:  PLoS One       Date:  2012-03-05       Impact factor: 3.240

5.  Anti-tumour effects and pharmacokinetic profile of 17-(5'-isoxazolyl)androsta-4,16-dien-3-one (L-39) in mice: an inhibitor of androgen synthesis.

Authors:  I P Nnane; B J Long; Y Z Ling; D N Grigoryev; A M Brodie
Journal:  Br J Cancer       Date:  2000-07       Impact factor: 7.640

6.  The effect of two weeks of treatment with dutasteride on bleeding after transurethral resection of the prostate.

Authors:  Kyu Shik Kim; Won Sik Jeong; Sung Yul Park; Yong Tae Kim; Hong Sang Moon
Journal:  World J Mens Health       Date:  2015-04-23       Impact factor: 5.400

7.  Expression of CSF1, AR, and SRD5A2 during Postnatal Development of the Boar Reproductive Tract.

Authors:  Kimberley Katleba; Erin Legacki; Trish Berger
Journal:  Animals (Basel)       Date:  2022-08-24       Impact factor: 3.231

8.  A dual 5α-reductase inhibitor dutasteride caused reductions in vascular density and area in benign prostatic hyperplasia.

Authors:  Masayoshi Zaitsu; Akiko Tonooka; Koji Mikami; Mami Hattori; Yuta Takeshima; Toshimasa Uekusa; Takumi Takeuchi
Journal:  ISRN Urol       Date:  2013-01-17

Review 9.  AR, the cell cycle, and prostate cancer.

Authors:  Steven P Balk; Karen E Knudsen
Journal:  Nucl Recept Signal       Date:  2008-02-01

10.  Seoritae extract reduces prostate weight and suppresses prostate cell proliferation in a rat model of benign prostate hyperplasia.

Authors:  Hoon Jang; Woong-Jin Bae; Seung-Mo Yuk; Dong-Seok Han; U-Syn Ha; Seong-Yeon Hwang; Shin-Hee Yoon; Sae-Woong Kim; Chang-Hee Han
Journal:  Evid Based Complement Alternat Med       Date:  2014-02-19       Impact factor: 2.629

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.